Trademark Overview
On Friday, March 15, 2024, a trademark application was filed for ONCOLYTIC IMMUNOTHERAPY with the United States Patent and Trademark Office. The USPTO has given the ONCOLYTIC IMMUNOTHERAPY trademark a serial number of 98452032. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Wednesday, September 25, 2024. This trademark is owned by CG Oncology, Inc.. The ONCOLYTIC IMMUNOTHERAPY trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical products for the treatment of cancer; pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing
Pharmaceutical research and development; Providing medical and scientific research information in the fields of oncology, autoimmune disorders, immunotherapy, immunotherapeutics, biotechnology, biopharmaceuticals, pharmaceuticals, therapies, diseases, and disorders
